RxDoctor Payments Data

Aaron Hupman, MD

General Practice · Lilburn, GANPI 1184764128

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $10,000 of the $11,216 with a category attached, or 89.2%. AbbVie accounts for 92.4% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2021 at $10,107 and has fallen 98.8% since, to $119 in 2025. Among general practice clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,216in general payments, 2019–2025

Across 66 payments — averaging $169.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$10K
  • AstraZeneca$266
  • Amgen$156
  • Boehringer Ingelheim$101
  • Novo Nordisk$87
  • Amarin Pharma, Inc.$85
  • plus $158 from 6 others

What the payments were for

  • Speaking & faculty fees$10,00089%
  • Food & beverage$1,17010%
  • Education$460%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,216 in reported general payments places this provider in the 95th percentile of 2,542 general practice providers in Georgia.

See all general practice providers in Georgia

Medicare billing

Part B allowed, 2024
$54,253
Medicare patients
123
Services billed
1,599

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide45$62,482
FarxigaDapagliflozin Propanediol23$24,824
MyrbetriqMirabegron34$21,845
GlyxambiEmpagliflozin/Linagliptin14$17,949
SynthroidLevothyroxine Sodium31$4,101
Advair HfaFluticasone Propion/Salmeterol12$3,889
Lisdexamfetamine Dimesylate13$3,074
Rosuvastatin Calcium147$2,011
Levothyroxine Sodium114$1,435
Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med11$1,346
Adacel TdapDiph,pertuss(Acell),tet Vac/Pf19$1,324
Atorvastatin Calcium116$1,086
Temazepam12$1,072
Azelastine Hcl28$942
Gabapentin42$926

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$87$62,48245 claims
AstraZenecaFarxiga$266$24,82423 claims
Boehringer IngelheimGlyxambi$101$17,94914 claims
AbbVieSynthroid$10,363$4,10131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,542 general practice providers in Georgia.

Other general practice in Lilburn

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →